# A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer

> **NCT07231094** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **The Third Xiangya Hospital of Central South University** · enrollment: 13 (estimated)

## Conditions studied

- Pancreatic Cancer Metastatic

## Interventions

- **BIOLOGICAL:** SapDM275 Tumor Vaccine Injection

## Key facts

- **NCT ID:** NCT07231094
- **Lead sponsor:** The Third Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2027-11
- **Final completion:** 2028-12
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07231094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07231094, "A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07231094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*